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Summary. Background: Novel pentapeptides called Throm-
bostatin FM compounds consisting mostly of D-isomers and
unusual amino acids were prepared based upon the stable
angiotensin converting enzyme breakdown product of brady-
kinin –RPPGF.Methods and Results:These peptides are direct
thrombin inhibitors prolonging the thrombin clotting time,
activated partial thromboplastin time, and prothrombin time at
‡0.78, 1.6, and 1.6 lM, respectively. They competitively inhibit
a-thrombin-induced cleavage of a chromogenic substrate at
4.4–8.2 lM. They do not significantly inhibit plasma kallikrein,
factor (F) XIIa, FXIa, FIXa, FVIIa-TF, FXa, plasmin or
cathepsin G. One form, FM19 [rOicPaF(p-Me)], blocks a-
thrombin-induced calcium flux in fibroblasts with an IC50 of
6.9 ± 1.2 lM. FM19 achieved 100% inhibition of threshold a-
or c-thrombin-induced platelet aggregation at 8.4 ± 4.7 lM
and 16 ± 4 lM, respectively. The crystal structure of thrombin
in complex with FM19 shows that the N-terminal D-Arg
retrobinds into the S1 pocket, its second residue Oic interacts
with His-57, Tyr-60a and Trp-60d, and its C-terminal p-methyl
Phe engages thrombins aryl binding site composed of Ile-174,
Trp-215, and Leu-99. When administered intraperitoneal,
intraduodenal, or orally to mice, FM19 prolongs thrombin
clotting times and delays carotid artery thrombosis.Conclusion:
FM19, a low affinity reversible direct thrombin inhibitor, might
be useful as an add-on agent to address an unmet need in
platelet inhibition in acute coronary syndromes in diabetics and
others who with all current antiplatelet therapy still have
reactive platelets.
Keywords: bradykinin, thrombin, thrombininhibitor, thrombo-
statin, platelets, RPPGF.
Introduction
Oral antiplatelet therapy has become the mainstay of pharma-
cologic treatment for the prevention of adverse thrombotic
cardiovascular events. Aspirin and clopidogrel are the currently
available oral antiplatelet agents [1]. Growing evidence indi-
cates that reduced responsiveness to the current antiplatelet
agents is associated with adverse clinical coronary artery events
[2]. In diabetic patients, a quartile can be found who even with
aspirin and clopidogrel therapy have highly reactive platelets
that are predictive of future coronary events [3]. Alternatively,
more potent P2Y12 antagonists reduce coronary events with
the trade-off of increased significant bleeding summating in no
improvement in overall outcome [4]. Thus, additional antiplat-
elet agents are needed that provide novel mechanisms for
platelet inhibition with reduced bleeding risk.
The angiotensin-converting enzyme (ACE) breakdown
product of bradykinin, RPPGF, inhibits thrombin-induced
platelet aggregation, inhibits protease activated receptor 1 and
4 (PAR1 and PAR4) mediated calcium mobilization, prolongs
clotting assays, prolongs the time for thrombosis in mouse
carotid injury models, and when infused in man inhibits
thrombin-induced platelet activation [5–9]. Using RPPGF as a
model sequence, studies substituted natural amino acids with
D-isomers and/or unusual amino acids to make compounds
more potent and resistant to degradation in biologic fluids.
TH146 (rOicPGF) was the first generation change with a D-
arginine and an Oic in residues 1 and 2 of the sequence,
respectively [7]. It is 4- to 5-fold more potent than RPPGF [7].
Additional studies increased the potency and in vivo stability of
TH146 by substitutions of the fourth and fifth amino acid
residues of the sequence (Table 1) [10]. The present investiga-
tions describe the mechanism of action, in vivo effect, and oral
availability of the compounds, called ThrombostatinTM FM,
with these latter modifications.
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Materials and methods
Peptides and reagents
Standard single letter abbreviations are used for L-amino acids
and lowercase letters are used to designate D-amino acids. The
synthetic amino acid (2S, 3aS, 7aS)-octahydroindol-2-carboxlic
acid is abbreviated (Oic). Peptides Arg-Pro-Pro-Gly-Phe
(RPPGF) and D-Arg-Oic-Pro-Gly-Phe (rOicPGF or TH146)
were synthesized byMultiple Peptide Systems, Inc., San Diego,
CA, USA (Table 1). The FM series of compounds (Table 1)
were prepared as previously described [10]. The structure of
FM19 [rOicPaF(p-Me)] is shown in Fig. 1. All peptides used in
these studies were greater than 95% pure and characterized by
analytical HPLC, amino acid analysis, and mass spectrometry.
The peptides were colorless, odorless, and soluble in water.
Platelet aggregation
Each peptide was screened for its ability to inhibit c-thrombin-
induced platelet aggregation. Fresh whole blood was used to
prepare platelet-rich plasma (PRP) and platelet aggregation
studies were performed as previously reported [7]. PRP was
treated with variable concentrations of c-thrombin
(3000 U mg)1, Haematologic Technologies, Essex Junction,
VT,USA) to determine theminimal or threshold concentration
for platelet aggregation. c-Thrombin was used as the platelet
agonist, as it does not proteolyze fibrinogen to form a fibrin
clot. The minimal concentration of each peptide to achieve
100% inhibition of threshold platelet aggregation was deter-
mined. In other experiments, platelets in PRP were washed by
gel filtration in HEPES-Tyrodes buffer and the minimal
concentration of FM19 and FM29 that inhibited threshold
human a-thrombin-induced (3000–3250 U mg)1, Haemato-
logic Technologies) platelet aggregation was determined [7].
Calcium mobilization
Each peptide was assayed for its ability to inhibit a-thrombin-
induced calcium mobilization in normal human lung fibro-
blasts, as previously reported [6,7]. The degree of inhibition of
a-thrombin-induced Ca2+ flux for each peptide was deter-
mined by calculating the area under the curve by Winlab
software (Perkin Elmer, Torrence, CA, USA) and is expressed
as percent activity; samples without peptide (thrombin alone)
were set to 100%.
Coagulation assays
The effect of FM19, FM29, FM33, or FM36 on the activated
partial thromboplastin time (APTT), prothrombin time (PT),
or thrombin clotting time (TCT) was determined as previously
described [6,7].
Inhibition of enzyme cleavage of chromogenic substrates
Inhibition of chromogenic activity of a-thrombin, was
determined by adding a-thrombin (0.5 nM) to 2–100 lM






(% inhibition at 5 lM)
RPPGF RPPGF 680 ± 280 –
TH146§ rOicPGF 140 ± 20 –
FM19 rOicPaF(p-Me) 16 ± 4 69
FM29 rOicPsF(p-Me) 16 ± 4 56
FM33 rOicPaF(p-Br) 18 ± 4 35
FM36 rOicPaF(p-I) 23 ± 3 36
FM39 rOicPaF(p-NO2) 33 ± 8 26
FM43 F(p-Me)OicrPa >1000 NI–
FM44 aPrOicF(p-Me) >1000 NI–
FM45 PaF(p-Me)rOic > 1000 NI–
FM46 PF(p-Me)Oicra 150 ± 70 NI–
FM47 PraF(p-Me)Oic >1000 NI–
FM48 PrOicF(p-Me)a >1000 NI–
*The minimal concentration for 100% inhibition of c-thrombin induced platelet aggregation ± SEM, n > 3. The percent inhibition of a-
thrombin-induced calcium mobilization at 5 lM peptide. From Hasan et al. [6]. §From Nieman et al. [7]. –No inhibition (NI) of a-thrombin-
















Fig. 1. The structure of FM19, rOicPaF(p-Me)–NH2.
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H-D-Phe-Pip-Arg-pNA (S2238) in the presence or absence of
FM compounds (3–30 lM) in 10 mM Tris-HCl and 150 mM
NaCl pH 8.0. Absorbance data for kinetic assays were collected
using a microplatelet reader (NOVAstar, BMG Labtech,
Offenburg, Germany; or Wallac Victor3 1420 Multilabel
Counter, PerkinElmer Life and Analytical Sciences, Boston,
MA, USA) and progress curves were plotted in Microsoft
Excel. Models of inhibition were determined according to the
Akaike Information Criteria (AIC) as calculated in SigmaPlot
(Systat Inc.) [11]. Additional studies determined the influence of
100–1000 lMFM19 on other coagulation proteases. Inhibition
of factor (F) VIIa (Haematological Technologies) in a
preformed complex with soluble recombinant tissue factor,
amino acids 1–219 (sTF1-219), provided by Dr Tom Girard
(Monsanto, St Louis, MO, USA), and inhibition of human
FXa and FXIa (Haematological Technologies) were per-
formed as previously described [7]. Inhibition studies of plasma
kallikrein or FXIIa (Enzyme Research Laboratories, Inc.,
South Bend, IN, USA) used 0.1–2 mM H-D-Pro-Phe-Arg-
p-nitroanalide (S2302) (Diapharma Chromogenix, Milano,
Italy) in 50 mMTris-HCl and 150 mMNaCl, pH 8.0. Inhibition
of Cathepsin G (Calbiochem) was determined with 0.36–
4.5 mM Suc-AAPF-p-nitroanalide (Calbiochem) in 100 mM
Tris-HCl and 500 mMNaCl in 10%DMSO, pH 7.4. Inhibition
of plasmin (Haematological Technologies) was determined
with 0.1–2 mM H-D-valyl-L-leucyl-L-lysine-p-nitroanilide
(S2251) in 10 mM Tris-HCl and 150 mM NaCl pH 8.0.
Crystallization of the thrombin-FM19 complex
Crystals of the complex of human thrombin R77aA and
inhibitor FM19 were grown by the hanging drop vapor-
diffusion method. The mutation R77aA abolishes the site of
autoproteolysis and confers improved stability to thrombin
for crystallization in the free form, or in complex with weak
active site inhibitors [12]. A solution of R77aA (5 mg mL)1 in
2 lL) in 50 mM choline chloride, 20 mM Tris, pH 7.4 was
mixed with an equal volume reservoir solution containing
20% PEG 3350, 100 mM Bis-Tris, pH 7.5 and 200 mM NaI,
and left to equilibrate at 23 C. Single crystals grew to an
approximate size of 0.45 · 0.15 · 0.1 lL in one to two weeks.
Crystals were hexagonal, space group P6122, with unit cell
parameters a = b = 80.9 Å, c = 183.7 Å, and contained
one molecule per asymmetric unit. X-ray data were collected
to 1.8 Å resolution from a crystal soaked in Paraffin oil
(Hampton Research, Aliso Viejo, CA, USA) for 5 min at
100K on an ADSC Quantum-315 CCD detector at the
Biocars Beamline 14-BM-C of the Advanced Photon Source,
Argonne National Laboratories, Argonne, IL, USA. Data
processing including indexing, integrating, and scaling was
performed using the HKL2000 package [13]. The structure
was solved by molecular replacement with MOLREP from
the CCP4 package [14] using the coordinates of the PPACK-
inhibited form of human thrombin R77aA [Protein Data
Bank (PDB) ID code 1SFQ] [12] as a starting model, with
inhibitors, sugars, and solvent molecules omitted as the
starting model. Refinement and electron density generation
were performed with the Crystallography and NMR System
software package [15] and 5% of the reflections were
randomly selected as a test set for cross validation. Rama-
chandran plots were calculated using PROCHECK [16].
Results of data collection, processing, and refinement are
listed in Table 4. Coordinates of the structure of the human
thrombin–FM19 complex have been deposited to the PDB
(PDB ID code 3BV9).
Pharmacokinetic and metabolic studies
Purpose-bred beagle dogs (9–11 kg) were prepared for the
pharmacokinetics studies as previously reported [7]. After a
single intravenous administration of FM19 (4.4 mg kg)1 in
5 mL saline infused over 1 min into each of four different
dogs), blood samples were collected at 1, 5, 10, 15, 20, 25, 30,
40, 60, 90, and 120 min by withdrawing 5 mL blood into a
syringe containing 3.8 g% sodium citrate (1:9, citrate:blood) to
prepare platelet-poor plasma that was stored in small aliquots
at )70 C until assay [7]. Similarly, five male and five female
Sprague–Dawley rats were injectedwith 17 mg kg)1 FM19 in a
dose volume of 5 mL kg)1 over 5 min and samples were
collected for analysis. The pharmacokinetic characteristics were
calculated using non-compartmental methods of Rowland and
Tozer [17]. FM19 in canine and rat plasma was assayed by
liquid chromatography/mass spectroscopy/mass spectroscopy
(LC/MS/MS) assay (see Supplementary material). The meta-
bolic stability of FM19 in liver microsomes from human,
canine, and rat hepatocytes was also performed (see Supple-
mentary material).
Mouse thrombosis studies
Mice, 8–16 weeks of age, were prepared for carotid artery
thrombosis studies using Rose Bengal (4, 5, 6, 7-tetrachloro-
3¢, 6-dihydroxy-2, 4, 5, 7-tetraiodospiro (isobenzofuran-
1(3H), 9 [9H] xanthan)-3-1 dipotassium salt) (Fisher Scien-
tific, Fair Lawn, NJ, USA) as previously reported [7].
Thrombosis experiments were performed using three different
routes of FM19 administration: intraperitoneal (IP) injec-
tions, intraduodenal installation, and oral administration in
drinking water. In initial investigations, FM19 was given
between 0.2 and 3.22 mg kg)1 IP. In other experiments, a
celiotomy was performed and after isolation of the proximal
duodenum, FM19 was instilled by intraluminal injection at
8.25, 16.5, or 33 mg kg)1 using 25 gauge needle injections.
Plasma samples were collected for coagulation studies and
other animals were examined on the thrombosis assay.
Experiments also were performed in mice by adding FM19
(3, 5, or 10 mg mL)1) to the drinking water. After two to
seven days, the mice were examined for their time to
thrombosis (Rose Bengal) assay and plasmas were used
to determine FM19 levels by LC/MS/MS assay while
plasmas from other treated animals was sampled for
FM19s influence on the TCT assay.
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Statistical analysis
Comparison between groups was made by the Students t-test
using non-paired data with a non-parametric analysis (Prism,
Graphpad Software Inc., SanDiego, CA,USA). Significance is
defined as a P-value < 0.05.
Results
Initial investigations determined which of the rOicPGF analogs
with substitutions at residues 4 and 5 were most potent
inhibitors of c-thrombin-induced platelet aggregation in PRP
(Table 1) [7]. The minimal concentration of peptide required
for 100% inhibition of threshold c-thrombin-induced platelet
aggregation was determined and compared to RPPGF and
TH146. The top five peptides were 4- to 9-fold more potent
than TH146 and twenty- to forty-threefold more potent than
RPPGF (Table 1). Two peptides, FM19 and FM29, were
chosen for further study. Five scrambled analogs of FM19
[rOicPa(p-Me)], FM43, FM44, FM45, FM47, and FM48, each
containing the same amino acids as FM19, but in a different
sequence, did not inhibit c-thrombin-induced platelet aggrega-
tion at 1000 lM (Table 1). A sixth scrambled analog, FM46,
did inhibit c-thrombin-induced platelet aggregation at 150 lM;
however, this potency is tenfold lower than that of FM19.
When using gel-filtered human platelets, FM19 and FM29
were found to inhibit threshold (2 nM) a-thrombin-induced
platelet aggregation 100% at 8.4 ± 4.7 lM and 11 ± 2.9 lM
(mean ± SEM, n = 5), respectively.
Investigations next determined the ability of these peptides to
inhibit a-thrombin-induced calcium mobilization in normal
human lung fibroblasts. Studies determined the percent inhibi-
tion at 5 lM for each peptide (Table 1). The most potent
inhibitors of calcium mobilization were FM19 and FM29 with
69and56percent inhibition, respectively.Thepercent inhibition
forFM33,FM36, andFM39was 2- to 3-fold lower thanFM19
(Table 1). Importantly, scrambled versions of FM19 (FM43–
48) did not inhibit calcium mobilization at either 5 or 20 lM
peptide (Table 1). FM19 and FM29 inhibited a-thrombin-
inducedCa2+fluxwithan IC50of 6.9 ± 1.2 and5.4 ± 1.9 lM,
respectively (P = 0.54; Fig. 2). The IC50 of these peptides is
nineteenfold lower than TH146 (130 ± 17 lM) [7].
Previous studies determined that both RPPGF and TH146
inhibit coagulation assays [6,7]. There was significant prolon-
gation (P < 0.05) of the APTT at 1.6 and 3.1 lM for FM19
and FM29, respectively (Fig. 3A, Table 2). The APTTwas less
affected by FM33, FM36, and FM39. The PTwas significantly
prolonged at 1.6 lM for FM19 and FM29, but less influenced
by FM33, FM36, and FM39 (Fig. 3B, Table 2). At 6.3 lM,
FM29 and FM19 prolonged the APTT and PT 24–25% and
17–30%, respectively. In contrast, the TCT was significantly
prolonged at 0.78 lM for each peptide with the exception of
FM29, which was significant at 0.39 lM (Fig. 3C, Table 2). At
1.6 lM, FM29 and FM19 prolonged the TCT 33 and 45%,
respectively. The latter data indicated that these compounds
are direct thrombin inhibitors.
Since bradykinin, RPPGF, and TH146 (Ki = 97 lM) bind
directly to the active site of thrombin to interfere with its
enzymatic activity [6,7,18], investigations determined the
concentration of the FM compounds required to inhibit
a-thrombin. FM19 was a direct competitive inhibitor of
a-thrombin with a Ki of 4.4 ± 2.4 lM (Fig. 4, Table 3).
Similarly, FM29, FM33, FM36, and FM39 were also
competitive inhibitors of a-thrombin with a Ki of 5.1 ± 2.6,
8.2 ± 3.3, 4.1 ± 1.3, and 9.8 ± 3.8 lM, respectively
(mean ± 95% confidence interval, Table 3). The data were
fit to eight models of enzyme inhibition based on a global
analysis. The best fits were chosen by the AIC, as previously
described [11]. In each case, the data clearly fit to a competitive
model. These data are supported by crystallography (Fig. 5).
Although each peptide inhibited thrombins enzymatic activity
to a similar degree, FM19 was chosen for further investigation
because it was the most active compound across most assays.
On enzymatic assays unique for each enzyme, FM19 did not
inhibit FXIIa, FVIIa-TF, FIXa, FXIa, plasma kallikrein,
plasmin or cathepsin G at 1.0 mM (data not shown). FM19
inhibited FXa with a Ki of 510 lM. Therefore, FM19 is a
relatively specific inhibitor of a-thrombin that has a twentyfold
more potent Ki than TH146 [7].
Crystallography
Human thrombin carrying the single Ala substitution of Arg-
77a in exosite I was crystallized in complex with FM19 at a
















Fig. 2. Influence of FM19 andFM29 on a-thrombin-induced intracellular
calcium mobilization. Normal lung fibroblasts were loaded with Fura-2
and incubated in the absence or presence of FM19 (d) or FM29 (s).
After incubation, cells were treated with the minimal concentration of
human a-thrombin that induces calcium mobilization. Values for each
concentration of peptide were determined by calculating the area under the
curve and are expressed as percentage of calcium flux. Samples with no
peptide inhibitor were set to 100%. The data represent the mean ± SD of
at least three experiments. The best fit was determined by a four parameter
logistical function.
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the PPACK-inhibited Na+-bound form of thrombin [12], with
a root-mean-squared deviation (rmsd) of only 0.325 Å
(Table 4). The inhibitor penetrates the active site of the enzyme
in the unusual retro-binding orientation (Figs. 5A and B) as
first observed for the RPPGF peptide [6]. Notably, FM19
makes few polar contacts with thrombin, and the only direct
interaction is mediated by H-D-Arg. The NH2 atom engages
the Od2 atom of Asp-189 (2.83 Å), O atom of Gly-218
(3.05 Å), and O atom of Ala-190 (3.38 Å) in H-bonding
interactions. TheNH1 atom formed aH-bond to theOd1 atom
of Asp-189 (3.00 Å). Finally, the N atom establishes a weaker
H-bond with the O atom of Gly-219 favored by its flipped
conformation in the enantiomeric D form. The rest of the polar
interactions are mediated by four water molecules (w113, w59,
w77, and w43) sandwiched between the inhibitor and the 216–
219 b-strand of thrombin (Fig. 5B). Water w113 bridges the O
terminal atom of FM19 (2.89 Å) and the Oe2 atom of Glu-217
(2.67 Å). Water w59 close by bridges the O terminal atom of
FM19 (2.70 Å) and the N atom of Gly-219 (3.27 Å). Water
w77 bridges the N atom of H-D-Ala of FM19 (2.95 Å) and the
N atom of Gly-219 (3.48 Å). Finally, water w43 establishes













































Fig. 3. Influence of FM compounds on coagulation assays. Normal hu-
man plasma was incubated with FM19 (d), FM29 ( ), FM33 ( ), FM36
( ) or FM 39 ( ) and the activated partial thromboplastin time (A),
prothrombin time (B), and thrombin clotting time (C) were determined as
described in Materials and Methods. The data represent the mean ± SD
of at least three independent experiments. The horizontal dashed line
represents the assay in the absence of peptide.
Table 2 Influence of FM compounds on clotting assays
Peptide
Minimal concentration (lM) for prolongation
(P < 0.05)
APTT PT TCT
TH146* 31 62 7.8
FM19 1.6 1.6 0.78
FM29 3.1 1.6 0.39
FM33 12.5 6.3 0.78
FM36 25 6.3 0.78
FM39 50 6.3 0.78
*From Nieman et al. [7]. APTT, activated partial thromboplastin time;
















Fig. 4. a-Thrombin cleavage of S2238 in the absence or presence of
FM19. a-Thrombin (0.5 nM) was added to S2238 (2–100 lM) in the
absence (d) or presence of 3 (s), 6 (.) or 12 (,) lMFM19. Initial velocity
data were fit to eight models of enzyme inhibition using a global
analysis nonlinear least-squares analysis to determine the Ki and type
of inhibition (see Methods). The data represent the mean ± SD of
at least three independent experiments.




FM19 4.4 ± 2.4 C*
FM29 5.1 ± 2.6 C
FM33 8.2 ± 3.3 C
FM36 4.1 ± 1.3 C
FM39 7.5 ± 3.2 C
C, competitive inhibition. *In 10 mM Tris-HCl, 150 mM NaCl at pH
8.0 and 25 C. With a ± 95% confidence interval.
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(3.09 Å) with the O atom of Gly-216 (2.79 Å). These water-
mediated interactions likely add specificity to binding and
suggest ways to optimize FM19 further. The bulk of the
binding epitope is provided by extensive hydrophobic interac-
tions. The bicyclic side chain of Oic engaged in van der Waals
interactions with the catalytic His-57, Tyr-60a, and Trp-60d,
whose indole ring is shifted >4 Å relative to the position seen
in the 1SFQ structure of thrombin [12]. The second Pro ring
makes no contact with the enzyme, but causes the side chain of
Glu-192 to relocate and establish a strong H-bond (2.88 Å)
with the side chain of Lys-149e in the hinge region of the
autolysis loop. This interaction is rarely observed in thrombin
structures and has the unusual consequence of stabilizing the
entire autolysis loop with additional strong H-bonds between
the Oc atom of Thr-149 and the N atom of Val-149c (3.02 Å),
and N atom of Thr-149 and the O atom of Val-149c (2.78 Å).
Further downstream from the second Pro ring, the methyl
group of H-D-Ala is free of contacts, but the terminal p-methyl
substituted Phe ring engages the aryl binding site of thrombin
composed of Ile-174, Trp-215, and Leu-99 in extensive van der
Waals interactions. These interactions are similar to those seen
between the aryl binding site and the P3H-D-Phe residue of the
active site inhibitor PPACK [12,19]. The interaction is unique
over previous versions (e.g. RPPGF) and surely contributes to
the added potency of the compound. However, the Oic side
chain interacts with the 60-loop of thrombin in a way that
resembles the P2 Pro residue of PPACK [12,19]. In summary,
the interaction of FM19 with thrombin is driven mainly by
polar contacts of the H-D-Arg residue with the primary
specificity pocket, hydrophobic interactions of the P2 Oic and
p-methyl substituted Phe with the 60-loop and the aryl binding
site, respectively. Additional strength to the binding interaction
comes fromwater-mediated contacts with the 216–219 b-strand
of the enzyme.
In vivo investigations
Initial investigations determined the pharmacokinetic profile of






















Fig. 5. Structure of the human thrombin mutant R77aA in complex with
the inhibitor FM19. (A) Thrombin is rendered as a ribbon colored
according to the spectrum (N-terminus blue, C-terminus red) and the
bound FM19 is rendered in CPK with C atoms in green. Relevant regions
of the enzyme are labeled. The bound Na+ is in red and the side chains of
Asp-189 in the primary specificity pocket and of residues of the catalytic
triad (His-57, Asp-102, and Ser1-95) are shown as sticks. Note the integrity
of the autolysis loop that is usually disordered in thombin structures. (B)
Details of the molecular contacts at the thrombin–FM19 interface, with
hydrophobic regions of the thrombin epitope colored in orange and polar
regions colored in light blue. The thrombin surface is rendered in wheat
and FM19 is in CPKmodel with C atoms in yellow. H-bonds are depicted
as broken lines. Water molecules mediating contacts with the 216–219 b-
strand of the enzyme are labeled in red.





Unit cell dimension (Å) a = 80.9, b = 80.9, c = 183.7
Molecules/asymmetric unit 1
Resolution range (Å) 40.0–1.8
Observations 247 117
Unique observations 32 820
Completeness (%) 96.9 (87.6)





Rcryst, Rfree 0.190, 0.239





Rmsd bond lengths* (Å) 0.012
Rmsd angles* () 1.7
Rmsd DB (Å2) (mm/ms/ss) 3.40/3.99/5.46
<B> protein (Å2) 26.8
<B> solvent (Å2) 34.2
<B> glycerol/Na+/I- (Å2) 52.8/22.5/29.7
Ramachandran plot
Most favored (%) 99.2
Generously allowed (%) 0.8
Disallowed (%) 0.0
mm, main chain–main chain; ms, main chain–side chain; ss, side
chain–side chain. *Root-mean-squared deviation (rmsd) from ideal
bond lengths and angles and rmsd in B-factors of bonded atoms.
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32.5 ± 2.9 min (mean ± SD) with a plasma clearance of
8.2 ± 5.1 mL min)1 kg)1 (Table 5). Similar investigations in
the conscious Sprague–Dawley rat showed a t1/2a of 27 ±
7 min with a plasma clearance of 10.9 ± 7 mL)1 min)1 kg)1.
FM19 is not metabolized in vivo. In pooled liver microsomes,
no significant metabolism (<20%) was observed after 120 min
at 1 and 10 lM concentrations with 1 mg mL)1 microsomal
protein.
Investigations next determined the influence of FM19 on
carotid artery thrombosis induced by free radical injury after
laser light on intravascular Rose Bengal. In C57BL/6j mice,
FM19 at ‡0.2 mg kg)1 IP significantly prolonged the time to
carotid artery thrombosis from 32 ± 2.5 min (untreated) to
38 ± 2.2 min (P = 0.04) or longer at higher concentrations of
added peptide (Fig. 6A).
Because FM19 does not contain a peptide bond between two
natural amino acids, studies determined it was stable in rat
intestinal juices (data not shown). Investigations next deter-
mined if FM19would be taken up in the intestine when instilled
into the duodenum. Instillation of 32 mg kg)1 FM19 in 100 lL
in the duodenum of B6129 mice resulted in a plasma
concentration of 1.53 lg mL)1 at 1 h as determined by
LC/MS/MS assay. Instillation of FM19 in the duodenum at
8.25, 16, or 33 mg kg)1 in B6129 mice resulted in a significant
prolongation (P < 0.0034) of the time of carotid artery
occlusion from 22 ± 2 min (control) (mean ± SEM) to
38 ± 4 min and 62 ± 8 min and in the 16 and 33 mg kg)1
FM19-treated mice, respectively (Fig. 6B). Furthermore, the
TCT in mice treated with 33 mg kg)1 in the duodenum
significantly increased from 21 s at baseline to 29 s at 30 min,
37 s at 1 h, and 50 s at 2 h (P £ 0.01). The APTT and PT
under the same conditions were significantly prolonged at 2 h
(P < 0.019) (data not shown).
Studies next determined if FM19 was effective after oral
administration. FM19 (3, 5 or 10 mg mL)1) was added to the
drinking water of B6129 mice for 7–10 days and the animals
were examined in the Rose Bengal carotid artery thrombosis
model (Fig. 6C). FM19 at 5 mg mL)1 or greater significantly
prolonged the time to thrombosis to 62 ± 7.1 min from
23 ± 1.1 min for untreated animals (P = 0.002). Further, the
TCT was prolonged from 24.3 ± 1.8 s in untreated mice to
175 ± 14 s (mean ± SD) with treatment. The murine plasma
level of orally administered FM19 after seven ormore days was
80 ± 9, 173 ± 16, or 244 ± 135 ng mL)1 (mean ± SD) for
3, 5, or 10 mg mL)1 in drinking water, respectively. Further
studies showed that just two days of 5 mg mL)1 FM19 in the
drinking water prolonged the time to thrombosis in these
animals to 46 ± 5 min with a TCT to 43 ± 3 s and a plasma
concentration of 128 ± 28 ng mL)1. These combined data




























































FM19 intraperitoneal (mg kg–1)
FM19 in duodenum (mg kg–1)












Fig. 6. Influence of FM19 on mouse carotid artery thrombosis initiated
by photooxidation of Rose Bengal. C57Bl/6j mice were prepared for Rose
Bengal studies to determine the time thrombosis in the absence or presence
of 0.2–3.22 mg kg)1 FM19 intraperitoneal injection (A). B6:129SF2/j
mice were prepared for Rose Bengal studies to determine the time
thrombosis in the absence or presence of 8.25–33 mg kg)1 FM19 injected
into the duodenum (B) or 3–10 mg mL)1 FM19 in the drinking water (C).
The data are the mean ± SD of at least three or more experiments.










Dog 1 330 5700 35 13
Dog 2 420 4900 30 12
Dog 3 960 2100 30 4.8
Dog 4 1500 1800 35 2.8
Mean ± SD 803 ± 542 3625 ± 1965 33 ± 2.9 8.2 ± 5.1
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Discussion
Previous studies demonstrate that the angiotensin-converting
enzyme (ACE) breakdown product, RPPGF, inhibits throm-
bin-mediated platelet aggregation in man and the time to
thrombosis in animal models [5–7,9]. Currently, we improved
the potency and stability of these compounds by substituting
D-isomers and/or unusual amino acids at residues 4 or 5 of the
previous lead compound, TH146 (rOicPGF) (Table 1) [7,10].
Five initial compounds inhibited threshold c-thrombin induced
platelet aggregation 4- to 9-fold better than TH146. Of these,
FM19 [rOicPaF(p-Me)] was chosen for further study. FM19
completely inhibited platelet aggregation at concentrations 9-
fold lower than TH146 and forty-threefold lower than RPPGF
(Table 1). FM19 was also a nineteenfold better inhibitor of
a-thrombin-induced calcium mobilization in human fibroblast
(IC50 = 6.9 lM for FM19 vs. 130 lM for TH146) and has a
twenty-twofold lower Ki (4.4 lM for FM19 vs. 97 lM for
TH146). These data demonstrate that changes at residues 4 and
5 result in a peptide that is twentyfold more potent than the
previous lead compound. The improved potency of FM19 over
TH146 is most likely attributed to the physical interaction of
the P5 p-methyl-substituted Phe ring of the C-terminal residue
with thrombin.
Kinetic analysis, X-ray crystallography and in vitro clotting
assays demonstrate that FM19, like previous iterations of
RPPGF derivates, interacts directly with thrombin. FM19 is a
competitive inhibitor (Ki = 4.4 lM; Fig. 4, Table 3) of throm-
bin cleavage of a chromogenic substrate (S2238). This assess-
ment is supportedbydirect crystallographicevidence thatFM19
binds to theactive siteof thrombin ina retro-bindingorientation
(Fig. 5). This interaction is largely mediated by its first residue
D-Arg. The structure of thrombin in complexwith the naturally
occurring peptide, RPPGF, also showed the N-terminal Arg
interacting with the S1 pocket in a retro-binding orientation [6].
In peptides where the N-terminal Arg is removed, there is no
inhibitory activity (Table 1). In contrast to RPPGF, the second
position of FM19, Oic, interacts with the 60-loop (Tyr60a and
Trp60d) moving the indole ring of Trp60d >4 Å. Further, the
Phe at residue 5 of RPPGF was not resolved from the density
map in the thrombin complex [6]. In contrast, residue5ofFM19
makes well-defined hydrophobic contacts with the aryl binding
pocket of thrombin, which is important for thrombins interac-
tion with polypeptide substrates [12,19]. These interactions
likely contribute to thefour hundredfold decrease in theKi of
FM19 vs. RPPGF (Fig. 4, Table 3) and theone hundred and
sixtyfold decrease in the minimal concentration required to
prolong in vitro thrombin clotting time (Fig. 3, Table 2) [6].
In addition to directly interacting with thrombin, previous
iterations of this group of compounds appeared to bind to the
exodomains of PAR1 and PAR4 at the thrombin cleavage
sites, preventing activation of these receptors [6–8]. Modifica-
tion of residues 4 and/or 5 of TH146 resulted in loss of this
activity while increasing its direct thrombin inhibition. FM19
was unable to consistently and specifically bind to recombinant
PAR1 or PAR4 exodomain in in vitro binding assays (data not
shown). Further, FM19 was unable to inhibit PAR1 or PAR4
activation by plasmin- or cathepsin G-induced Ca2+ mobili-
zation on HeLa cells transfected to express PAR1 or PAR4
(data not shown) [20,21]. It is possible FM19 binds to PAR1
and 4 such that it cannot block plasmin or cathepsin G
proteolysis of the exodomain. However, it is more likely that
the substitutions made at residues 4 and/or 5 alter the structure
of FM19 such that it improves its direct thrombin inhibition at
the expense of its binding to PAR1 and PAR4.
Although the Thrombostatin FMcompounds have lost their
ability to bind to PAR1 and PAR4, they represent an
improvement over previous iterations of these compounds
[7,22]. First, they are more potent in all assays [7,22]. Secondly,
as these compounds have no peptide bonds between two L-
amino acids, they are stable in biologic fluids allowing for oral
delivery. When animals were given ‡5 mg kg)1 FM19 orally
for two to seven days, the plasma levels of FM19 (128–
244 ng mL)1) were increased sufficiently to prevent arterial
thrombosis. Thirdly, the mechanism of action of the Throm-
bostatin FM compounds may make them more apt to inhibit
platelet thrombin receptor activation than other direct throm-
bin inhibitors. The fact that theN-terminalH-D-Arg fills the S1
pocket of the active site of thrombin may be particularly
effective to prevent PAR1 or PAR4 binding and activation.
Such a mechanism of inhibition may have improved inhibition
of platelet activation over more potent direct thrombin
inhibitors, such as hirudin or bivalirudin, which have to also
interact with thrombins exosite 1. Further, the potency and
irreversibility of an agent such as hirudin also increases bleeding
risk, which alone reduces overall clinical outcomes [4,23].
Previous studies have shown that cleaved PAR3 on murine
platelets binds to thrombins exosite 1 to open thrombins S1
pocket to facilitate PAR4 activation [24]. If a similar mecha-
nism occurs between cleaved PAR1 and PAR4 on human
platelets, FM19-like compounds may prove to be better direct
thrombin inhibitors to prevent platelet activation.
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